LIEBEL-FLARSHEIM FDA Approval NDA 019710

NDA 019710

LIEBEL-FLARSHEIM

FDA Drug Application

Application #019710

Documents

Letter2008-04-30
Letter2015-07-10
Label2015-07-09
Letter2008-04-28
Review1997-05-23
Label2016-08-17
Letter2016-08-12
Label2017-04-06
Letter2017-04-12
Label2017-04-27
Letter2017-05-02
Letter2020-01-24
Label2020-01-24
Letter2022-02-22
Label2022-02-23
Letter2022-05-05
Label2022-05-06

Application Sponsors

NDA 019710LIEBEL-FLARSHEIM

Marketing Status

Prescription001
Prescription002
Discontinued003
Prescription004
Prescription005

Application Products

001INJECTABLE;INJECTION68%1OPTIRAY 320IOVERSOL
002INJECTABLE;INJECTION51%1OPTIRAY 240IOVERSOL
003INJECTABLE;INJECTION34%0OPTIRAY 160IOVERSOL
004INJECTABLE;INJECTION64%1OPTIRAY 300IOVERSOL
005INJECTABLE;INJECTION74%1OPTIRAY 350IOVERSOL

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP1988-12-30STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL2AP1989-10-10STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL3AP1990-03-30STANDARD
EFFICACY; EfficacySUPPL4AP1992-01-22
MANUF (CMC); Manufacturing (CMC)SUPPL5AP1992-01-22STANDARD
EFFICACY; EfficacySUPPL7AP1992-07-09
MANUF (CMC); Manufacturing (CMC)SUPPL8AP1992-12-04STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL9AP1992-08-28STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL10AP1993-09-22STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL11AP1992-10-26STANDARD
EFFICACY; EfficacySUPPL12AP1992-12-11
MANUF (CMC); Manufacturing (CMC)SUPPL13AP1996-07-12STANDARD
EFFICACY; EfficacySUPPL16AP1993-03-09
EFFICACY; EfficacySUPPL17AP1993-07-27
EFFICACY; EfficacySUPPL18AP1995-06-21STANDARD
LABELING; LabelingSUPPL19AP1995-01-13STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL21AP1997-05-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL22AP1999-03-25STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL23AP1999-04-16STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL24AP1999-10-27STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL25AP2001-01-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL26AP2001-09-12STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL27AP2001-08-02STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL30AP2006-03-15N/A
LABELING; LabelingSUPPL32AP2008-04-25STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL33AP2007-08-28N/A
LABELING; LabelingSUPPL34AP2008-04-25STANDARD
LABELING; LabelingSUPPL35AP2009-08-08STANDARD
LABELING; LabelingSUPPL39AP2016-08-12STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL50AP2013-12-19STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL51AP2013-12-06STANDARD
LABELING; LabelingSUPPL52AP2015-07-06STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL53AP2016-05-13STANDARD
LABELING; LabelingSUPPL54AP2017-04-26STANDARD
LABELING; LabelingSUPPL55AP2017-04-05STANDARD
LABELING; LabelingSUPPL58AP2020-01-23STANDARD
LABELING; LabelingSUPPL64AP2022-05-04STANDARD
LABELING; LabelingSUPPL65AP2022-02-18STANDARD

Submissions Property Types

SUPPL2Null0
SUPPL3Null0
SUPPL5Null0
SUPPL8Null0
SUPPL9Null0
SUPPL10Null0
SUPPL11Null0
SUPPL13Null0
SUPPL21Null0
SUPPL22Null0
SUPPL23Null0
SUPPL24Null0
SUPPL25Null0
SUPPL26Null0
SUPPL27Null0
SUPPL35Null6
SUPPL39Null6
SUPPL50Null0
SUPPL51Null0
SUPPL52Null15
SUPPL53Null0
SUPPL54Null15
SUPPL55Null6
SUPPL58Null15
SUPPL64Null7
SUPPL65Null6

CDER Filings

LIEBEL-FLARSHEIM
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 19710
            [companyName] => LIEBEL-FLARSHEIM
            [docInserts] => ["",""]
            [products] => [{"drugName":"OPTIRAY 160","activeIngredients":"IOVERSOL","strength":"34%","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"OPTIRAY 240","activeIngredients":"IOVERSOL","strength":"51%","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"},{"drugName":"OPTIRAY 300","activeIngredients":"IOVERSOL","strength":"64%","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"},{"drugName":"OPTIRAY 320","activeIngredients":"IOVERSOL","strength":"68%","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"},{"drugName":"OPTIRAY 350","activeIngredients":"IOVERSOL","strength":"74%","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"01\/23\/2020","submission":"SUPPL-58","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/019710s058lbl.pdf\"}]","notes":""},{"actionDate":"04\/26\/2017","submission":"SUPPL-54","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/019710s054,020923s019lbl.pdf\"}]","notes":""},{"actionDate":"04\/05\/2017","submission":"SUPPL-55","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/019710s055lbl.pdf\"}]","notes":""},{"actionDate":"08\/12\/2016","submission":"SUPPL-39","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/019710s039,020923s009lbl.pdf\"}]","notes":""},{"actionDate":"07\/06\/2015","submission":"SUPPL-52","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/019710s052,020923s018lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"OPTIRAY 160","submission":"IOVERSOL","actionType":"34%","submissionClassification":"INJECTABLE;INJECTION","reviewPriority":"Discontinued","inserts":"[]","notes":">No"},{"actionDate":"OPTIRAY 240","submission":"IOVERSOL","actionType":"51%","submissionClassification":"INJECTABLE;INJECTION","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"},{"actionDate":"OPTIRAY 300","submission":"IOVERSOL","actionType":"64%","submissionClassification":"INJECTABLE;INJECTION","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"},{"actionDate":"OPTIRAY 320","submission":"IOVERSOL","actionType":"68%","submissionClassification":"INJECTABLE;INJECTION","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"},{"actionDate":"OPTIRAY 350","submission":"IOVERSOL","actionType":"74%","submissionClassification":"INJECTABLE;INJECTION","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"}]
            [supplements] => 
            [actionDate] => 2020-01-23
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.